INTRODUCTION
============

Major depression is a highly debilitating and life-threatening disorder with a lifetime prevalence of 16.5% ([@bib37]) affecting 6.9% of the population every year ([@bib88]). Available treatments include pharmacological approaches targeting mainly monoaminergic systems and non-pharmacological treatments, including psychotherapy, vagus nerve stimulation, transcranial magnetic stimulation, and electroconvulsive treatment ([@bib58]). Nevertheless, a significant number of patients remains inadequately treated displaying non-response or partial response after all treatment options have been explored (for a review see [@bib1]; [@bib83]). This treatment-resistant depression (TRD) is particularly associated with great economic burden ([@bib21]), high social and familial impact (for a review see [@bib49]), and personal suffering. New hope is now given to these individuals by clinical studies demonstrating long-term effects of high-frequency deep brain stimulation (DBS) in terms of improving depressive symptoms of helplessness, anhedonia and anxiety, and, thus, enhancing quality of life ([@bib6]; [@bib47]). Interestingly, physical and psychiatric side effects elicited by DBS can be minimized or abolished by adjustment of the stimulation settings ([@bib6]) or, if unacceptable, DBS can be stopped at any time according to the basic principles of medical ethics and, in particular, those issues pertinent to DBS treatment ([@bib73]).

Although the ideal targets of DBS for eliciting therapeutic effects in TRD are a matter of debate ([@bib46]), it has been suggested that any brain region of the proposed dysfunctional depression neurocircuitry ([@bib41]) may be interesting as affected network components are overlapping ([@bib27]). Accordingly, DBS has been applied to the subgenual cingulate cortex ([@bib47]), the ventral striatum ([@bib51]), the nucleus accumbens (NAcb) ([@bib6]), and the lateral habenula ([@bib33]) of small TRD patient populations. Specifically, promising results have been obtained by DBS to the NAcb (NAcb-DBS), which has induced solid antidepressant, anxiolytic, and antianhedonic effects in patients with TRD ([@bib6]). The unique position of the NAcb in the brain enables it to act as a gateway for information being transmitted from emotional centers to motor control regions ([@bib28]). Functionally, the NAcb processes reward and pleasure information and is dysfunctional in patients suffering from depression ([@bib79]). This is relevant, as anhedonia is one of the core symptoms of depression and reflects a lack of reward and reward-motivated behavior ([@bib26]). The NAcb receives inputs from midbrain areas, such as the ventral tegmental area, the medial substantia nigra, the dorsal and medial raphe nuclei, the locus coeruleus, as well as from limbic structures, including the amygdala, the hippocampus (HPC), and the prefrontal cortex ([@bib61]). In turn, it projects to cortical areas (including the infralimibic cortex and the orbitofrontal cortex (OFC)), and to the ventral pallidum, the thalamus, the amygdala, and the hypothalamus ([@bib35]). Interestingly, as projections of the NAcb are glutamatergic as well as GABAergic, stimulation of the NAcb can modulate neuronal activity of emotion and motivation centers implicated in the pathophysiology of depression in a dual way (also see [@bib74]).

The mechanisms through which DBS act are poorly understood ([@bib40]). While early observations in Parkinson patients led to the proposal of a functional block of the target region by DBS ([@bib3]), it is thought nowadays that DBS causes axonal activation and neuronal inhibition ([@bib15]; [@bib84]; see also [@bib55]; [@bib62], [@bib63]). Therefore, clinically relevant animal models are pivotal to further study the neurobiological mechanisms underlying the beneficial effects of NAcb-DBS.

This study was aimed at providing the first comprehensive behavioral evaluation of NAcb-DBS in the HAB mouse line selectively bred for high trait anxiety ([@bib44]; [@bib69]). A characteristic comorbidity in HAB mice is the preference of immobility/passive stress-coping strategies, indicative of enhanced depression-related behavior reflecting depressive patients with comorbid anxiety. To gain insights into neurobiological mechanisms of action of successful NAcb-DBS treatment, we additionally studied stress-induced expression of the immediate-early gene c-Fos as the marker for neuronal activation, as well as a possible alteration of the amount of newly born cells and immature neurons in HAB mice. These sets of experiments were stimulated by studies showing that clinically established antidepressant drugs affect deranged bran activity patterns and adult hippocampal neurogenesis in humans and/or rodents (for a review see [@bib68]).

MATERIALS AND METHODS
=====================

Animals
-------

Experiments were carried out on male (12--15 weeks old) HAB and normal depression/anxiety animals (NAB) mice bred for their innate level of anxiety-related behavior at the Department of Pharmacology and Toxicology (University of Innsbruck, Austria) (for details see [@bib69]). Animals were group-housed under standard laboratory conditions (12 : 12 light/dark cycle with lights on at 07:00 hours, 22±2 °C, 50--60% humidity) with pelleted food and water available *ad libitum*. All experiments were designed to minimize animal suffering as well as the number of animals used. Experiments comprising this study were approved by the national ethical committee on animal care and use (Bundesministerium für Wissenschaft und Forschung) in compliance with international laws and policies.

Drug Treatments
---------------

Reboxetine (40 mg/kg per day; Ochem, Chicago, IL), desipramine (30 mg/kg per day; Sigma-Aldrich, Vienna, Austria), fluoxetine (18 mg/kg per day; Eubio, Vienna, Austria), paroxetine (10 mg/kg per day; Ochem), and citalopram (10 mg/kg per day, kindly provided by Lundbeck, Denmark) were administered via the drinking water for 3 weeks. A drug intake of the dose indicated above was achieved by adapting the concentrations of the drug in the drinking solutions according to mean drinking volume and body weight per cage ([@bib71]). Mice were kept on drug treatment until completion of all experiments. Control mice received tap water. 5-Bromo-2′-deoxyuridine (BrdU) (Sigma-Aldrich) was injected at a dose of 100 mg/kg (intraperitoneally) once per day for 4 days for the labeling of newly born cells.

Deep Brain Stimulation
----------------------

Before surgery, animals were handled for 3 days to habituate them to the experimenter and the stimulation procedure. Using a stereotaxic frame, anesthetized animals (ketamine/xylazine 80/5 mg/kg, intraperitoneally) were implanted with electrodes (MS303-3-B-SPC, bipolar, twisted, 8 mm; Plastics One, Roanoke, VA) reaching the NAcb core (coordinates: 1.10 mm anterior, 1.45 mm lateral, and 4.65 mm ventral to bregma). After surgery, animals were individually caged, and received buprenorphine (0.1 mg/kg intraperitoneally) every 8 h over 3 days to minimize pain. Following 4--5 days of recovery, animals received high-frequency stimulations daily (130 Hz, 100 μA, 60 μs pulse width; A310 Accupulser and A365 Stimulus Isolator; World Precision Instruments, Berlin, Germany) for 1 h per day (NAcb-DBS). Control animals (NAcb-sham) were connected to the stimulator without current being applied. At the end of the experiments, localization of electrodes in the NAcb was confirmed on cresyl violet-stained coronal sections (see Figure 2b). Animals with misplaced electrodes were excluded from all data sets.

Experiments
-----------

In Experiment 1, the sensitivity of HAB mice to the antidepressant efficacy of different selective serotonin reuptake inhibitors (SSRIs) was explored in the forced swim test (FST) ([Figure 1](#fig1){ref-type="fig"}). Experiments 2--4 ([Figure 2a](#fig2){ref-type="fig"}) were designed to investigate the effect of single and repeated NAcb-DBS (i) on the anxiety- and depression-related behavior displayed by HAB mice, using a battery of established tests, (ii) on adult hippocampal neurogenesis, and (iii) on challenge-induced neuronal activation patterns in different brain regions, using immunohistochemistry.

Behavior
--------

All behavioral tests were performed on HAB and NAB mice 1 h after completion of NAcb-DBS or NAcb-sham. The FST and tail suspension test (TST) were used to assess depression-like behavior (for a review see [@bib11]; [@bib12]). Anxiety-related behavior was investigated using the novelty-suppressed feeding paradigm, while general locomotor activity was measured in the open field. All behavioral tests were performed according to previous protocols established in our laboratory ([@bib71]; [@bib86]), details of which are provided in the [Supplementary Information](#sup1){ref-type="supplementary-material"}.

Immunohistochemistry
--------------------

At 2 h after the last challenge, when expression levels of c-Fos protein are at their peak ([@bib90]), mice were deeply anesthetized with an overdose of sodium pentobarbital (200 mg/kg) and transcardially perfused with saline followed by 4% paraformaldehyde (in 0.1 mol/l phosphate buffer, pH 7.4), as described previously ([@bib60]). One-in-eight of the free-floating coronal sections (50 *μ*m) throughout the entire murine HPC were processed for BrdU, doublecortin (DCX), and c-Fos immunohistochemistry, respectively, following established protocols ([@bib10]; [@bib60]). Sections were incubated with one of the following primary antibodies: rat anti-BrdU (1 : 350; Serotec, Dusseldorf, Germany), goat anti-DCX C18 (1 : 250; Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti c-Fos (1 : 10 000; Santa [C]{.ul}ruz Biotechnology). Subsequently, they were incubated with the corresponding biotinylated goat anti-rat, rabbit anti-goat, or goat anti-rabbit secondary antibody (all 1 : 200; Vector laboratories, Burlingame, CA). The formed antigen-antibody-complexes were visualized by the avidin-biotin-horseradish peroxidase procedure (Vectastain Elite ABC kit; Vector Laboratories) using 3,3′-diaminobenzidine as the chromogen.

Immunoreactive cells were quantified in the regions of interest using a light-optical microscope (Olympus, Vienna, Austria) and a computer-assisted image analysis system (cellSens Dimension; Olympus). A cell was considered as labeled (positive) for c-Fos, DCX, or BrdU when the brown-black DAB staining was unambiguously darker than the background, and this included all cells from low to high intensities of staining.

Data Analysis
-------------

Data are presented as mean±standard error of the mean (SEM). Exact *n* numbers are given in the table and figure legends. Statistical analysis was performed using STATISTICA 8.0 (StatSoft, Tulsa, OK) after data had been screened for outliers using the Grubb\'s test. All data were further tested for homoscedasticity using Levene\'s test. Data were statistically analyzed using one-way ANOVA (*post hoc* Bonferroni) or unpaired Student\'s *t*-test. Statistical significance was set at *P*\<0.05.

RESULTS
=======

HAB Mice Displayed Behavioral Insensitivity to SSRIs
----------------------------------------------------

To investigate whether the HAB mouse model mimics features of treatment resistance, we first examined the efficacy of different classes of antidepressant drugs in reducing the enhanced depression-like behavior displayed by HAB mice in comparison with NAB mice. Reproducing our previous results ([@bib66]), the immobility displayed in the FST was enhanced in HAB animals compared with their NAB counterparts. Chronic treatment with one of three SSRIs did not change the high immobility scores of male HAB mice in the FST (F~4,31~=156.8, *P*\<0.001; [Figure 1](#fig1){ref-type="fig"}). We observed that treatment resistance seemed to be restricted to drugs targeting solely the serotonergic system, as both the selective noradrenaline re-uptake inhibitor reboxetine and the tricyclic antidepressant desipramine significantly reduced the depression-like behavior of HAB mice assessed in the FST (F~2,22~=8.761, *P*=0.002) ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}).

NAcb-DBS Reduced Depression-Like Behavior in HAB, but not NAB Mice
------------------------------------------------------------------

We next examined whether NAcb-DBS would be able to alter the enhanced depression-like behavior of SSRI-insensitive HAB mice. A single session of NAcb-DBS had no effect and resulted in unaltered time spent immobile compared with NAcb-sham HAB animals both in the FST (*t*=0.576, *P*=0.577; [Figure 3a](#fig3){ref-type="fig"}) and TST (*t*=−0.580, *P*=0.573; [Figure 3b](#fig3){ref-type="fig"}). In contrast, HAB mice receiving repeated (7 × ) NAcb-DBS displayed a reduced amount of time spent immobile both in the FST (*t*=3.021, *P*=0.007; [Figure 3a](#fig3){ref-type="fig"}) and the TST (*t*=3.001, *P*=0.008; [Figure 3b](#fig3){ref-type="fig"}), indicating a robust antidepressant effect. Next, we investigated whether NAcb-DBS could affect the depression-like behavior of NAB mice, which similar to non-depressed human subjects ([@bib2]; [@bib25]) do not respond to pharmacological interventions ([@bib66]). Indeed, neither single (*t*=0.949, *P*=0.356) nor repeated (*t*=0.302, *P*=0.767) NAcb-DBS altered the depression-like behavior of NAB mice ([Supplementary Figure S2A](#sup1){ref-type="supplementary-material"}), suggesting that repeated NAcb-DBS is only effective in deranged, that is, pathophysiological, systems using the present stimulation conditions.

NAcb-DBS Reduced Anxiety-Related Behavior in HAB, but not NAB Mice
------------------------------------------------------------------

Given that HAB mice are characterized by enhanced anxiety-related behavior ([@bib43]), we also studied possible effects of NAcb-DBS on emotionality in HABs. In comparison with NAcb-sham HAB controls, four repetitions of NAcb-DBS greatly reduced the latency to eat a preferred food offered in the center of the testing area of the novelty suppressed feeding paradigm (*t*=3.064, *P*=0.007; [Figure 3c](#fig3){ref-type="fig"}), indicating a clear anxiolytic effect in HAB mice. In contrast, there was no significant anxiolytic effect of repeated NAcb-DBS as compared with NAcb-sham in NAB animals (*t*=1.684, *P*=0.111; [Supplementary Figure S2B](#sup1){ref-type="supplementary-material"}).

NAcb-DBS did not Influence Locomotor Activity of HAB Mice
---------------------------------------------------------

To exclude the possibility that the observed behavioral changes following repeated NAcb-DBS were affected by unspecific alterations in general locomotion, locomotor activity of animals was studied in an open field (see scheme in [Figure 2a](#fig2){ref-type="fig"}). Following five DBS stimulations, the distance traveled in the open field by HAB mice did not differ within the first 5 min (*t*=1.410, *P*=0.178), reflecting the testing period of the TST and FST, or during the total 10 min testing time (*t*=0.007, *P*=0.994; [Table 1](#tbl1){ref-type="table"}).

NAcb-DBS Enhanced Adult Hippocampal Neurogenesis in HAB Mice
------------------------------------------------------------

To examine possible underlying mechanisms of successful NAcb-DBS, we next studied whether repeated NAcb-DBS would increase adult hippocampal neurogenesis in HAB mice, as this has been previously shown for various other antidepressant interventions, including pharmacotherapy and electroconvulsive seizures (for a review see [@bib68]). Indeed, in HAB mice, DCX immunohistochemistry revealed an enhanced number of immature neurons in the dentate gyrus of the HPC following repeated NAcb-DBS as compared with NAcb-sham conditions (*t*=2.706, *P*=0.015; [Figures 4a and c](#fig4){ref-type="fig"} or *t*=2.914, *P*=0.001; [Figures 4e and g](#fig4){ref-type="fig"}). In addition, BrdU was injected either before NAcb-DBS or during NAcb-DBS (see [Figure 2a](#fig2){ref-type="fig"}, Experiments 3 and 4) to reveal putatively different effects of NAcb-DBS at different developmental stages of newly born cells. It was observed that the number of BrdU-positive cells was increased following NAcb-DBS treatment as compared with NAcb-Sham condition when BrdU was injected before NAcb-DBS (*t*=2.361, *P*=0.030; [Figures 4b and d](#fig4){ref-type="fig"}), but not during NAcb-DBS (*t*=0.268, *P*=0.792; [Figures 4f and h](#fig4){ref-type="fig"}).

NAcb-DBS Modulated Challenge-Induced Neuronal Activation Patterns in HAB Mice
-----------------------------------------------------------------------------

An overview of c-Fos expression in the analyzed brain areas and *P*-values are given in [Table 2](#tbl2){ref-type="table"}. Repeated NAcb-DBS modulated stress-induced neuronal activity in four out of seven investigated areas. In comparison with their NAcb-sham controls, in NAcb-DBS-treated HAB mice the numbers of c-Fos-positive cells were significantly enhanced in the lateral OFC, lateral habenula, and dentate gyrus of the HPC, while c-Fos induction was reduced in the prelimbic cortex only ([Figure 5](#fig5){ref-type="fig"}).

DISCUSSION
==========

The applicability of DBS is currently being evaluated in various psychiatric indications including TRD ([@bib19]; for a review see [@bib50]). Yet, the investigation of its underlying mechanisms is limited in humans for understandable reasons, and preclinical data showing the behavioral efficacy of DBS as well as its neurobiological correlates are rare in psychopathologically relevant animal models. Motivated by these facts, we initially further validated the unique HAB mouse model of comorbid trait anxiety- and depression-like behavior (Kromer *et al*, 2005; Landgraf *et al*, 2007; [@bib66]) by demonstrating that these mice are resistant to the antidepressant effects of chronic SSRI treatment, the first-line therapy for depression as well as many anxiety disorders ([@bib39]). In contrast, repeated NAcb-DBS rescued the enhanced depression- and anxiety-related behavior of HAB animals. This effect coincided with (i) distinct changes in stress-induced neuronal activation of depression-related brain areas, including cortical areas and the HPC, as well as (ii) increased adult hippocampal neurogenesis.

HAB Mice Displayed Features of TRD
----------------------------------

HAB mice display enhanced depression-like behavior as well as altered stress-induced neuronal activity in networks related to depression and anxiety in comparison with their normal depression/anxiety NAB counterparts ([@bib66]; [@bib70]). In this study, we demonstrate for the first time that male HABs are insensitive to at least three SSRIs differing in half-life, plasma-binding, active metabolites, and *K*~i~ values of 5-HT uptake ([@bib32]). Interestingly, we observed that treatment resistance seemed to be restricted to drugs targeting solely the serotonergic system, as both the selective noradrenaline re-uptake inhibitor reboxetine and the tricyclic antidepressant desipramine significantly reduced the depression-like behavior of HAB mice. This finding was surprising further suggesting that male HAB mice represent a valid model to study treatment resistance against SSRIs in humans. Indeed, at least 33% of patients do not respond to first-line pharmacotherapies such as the SSRI citalopram ([@bib39]; [@bib80]). Changed responsiveness to SSRI treatment in humans has been linked to SNPs affecting 5-HT synthesis and polymorphism in the 5-HTT promoter region as well as functional polymorphisms in the 5-HT~1A~ and 5-HT~1B~ receptor genes (for a review see [@bib42]). However, while an aberrant 5-HT neurotransmission has been reported in male HAB rats ([@bib34]), pathophysiological correlates underlying the selective insensitivity to SSRIs in HAB mice remain to be elucidated in further experiments.

To date, there are only a few reports on TRD in animal models of depression. For example, the Flinders sensitive rat line has recently been described as being insensitive to citalopram and nortryptilin when subjected to repeated maternal separation ([@bib7]; [@bib8]). Furthermore, congenital learned-helplessness rats and about a quarter of rats subjected to unpredictable mild stress do not respond to chronic treatment with desipramine or fluoxetine, or to electroconvulsive therapy, respectively ([@bib72]; [@bib85]). It is possible that in the past insensitivities to certain drug classes were less likely to be reported. However, more recently the restriction of predictive validity of animal models for depression has been (partially) eased as a consequence of the need to model TRD ([@bib7]; [@bib68]) and to test new antidepressant approaches not primarily acting via monoaminergic systems.

NAcb-DBS Elicited Antidepressant and Anxiolytic Effects in HAB Mice
-------------------------------------------------------------------

In this study, we show for the first time that NAcb-DBS reduced depression-like behavior in an SSRI-insensitive animal model for enhanced depression-like behavior. While acute stimulation was not sufficient, repeated high-frequency stimulation caused a robust antidepressant effect in HAB mice. Similarly, in patients with TRD, significant reductions in depressive symptomatology reaching response or remission end points also seem to require more time ([@bib5]; [@bib48]), despite some rapid effects on specific symptoms seen during or following early phases of DBS ([@bib74]; [@bib52]). These findings, thus, suggest that at least some of the behavioral changes induced by NAcb-DBS may require long-term changes such as modulation of neuroplasticity. Indeed, in rats, pERK expression (an early marker of cell plasticity) is enhanced in prefrontal and orbitofrontal regions as well as in the amygdala following DBS of the NAcb/ventral striatum ([@bib65]). In addition to its antidepressant effects, repeated NAcb-DBS reduced the enhanced trait anxiety of HAB mice to an extent comparable to that achieved after anxiolytic treatment ([@bib24]; [@bib43]; [@bib69]; for a review see [@bib70]). Underlining the translational value of the present findings in HAB mice, similar effects were also observed in humans ([@bib6]; [@bib13]).

Various behaviors, including locomotion, seem to be rapidly altered by interference with the NAcb function. As both ablation ([@bib64]) and electrical stimulation ([@bib82]) of the NAcb affect activity and exploratory behavior in animals and/or humans, we tested whether NAcb-DBS under our stimulation condition produces changes in general locomotor activity, which could potentially influence behavioral assessment of anxiolytic and antidepressant effects. This possibility could be excluded, as it was found that NAcb-sham and NAcb-DBS mice did not differ in terms of distance traveled in the open field, indicating no effect on locomotion using the present high-frequency stimulation settings.

To clarify whether the behavioral effects of NAcb-DBS were restricted to acting only on pathophysiologically deranged as opposed to physiological networks, we investigated the behavioral outcome of repeated NAcb-DBS in NABs. Neither single nor repeated NAcb-DBS affected the level of depression- and anxiety-like behavior in NAB mice, indicating that NAcb-DBS (at the chosen stimulation settings) preferentially acts on systems of altered/enhanced emotionality. In support of this idea, [@bib81] recently reported inefficacy of NAcb-DBS in terms of its ability to affect depression-like behavior displayed by normal rats. Mood-elevating effects of antidepressants are predominantly observed in depressed patients ([@bib2]; [@bib25]; [@bib89]), suggesting that the neurobiological targets of antidepressants in pathophysiologically deranged systems differ from those in intact systems ([@bib4]). Therefore, while some aspects of therapeutic efficacy of DBS may be shared by normal animals ([@bib29]; [@bib65]) and pathophysiological models ([@bib18]; [@bib23]; [@bib30]), some critical changes underlying their antidepressant effect will remain undetected if animals reflecting physiological but not pathophysiological conditions are used.

Neurobiological Changes Induced by NAcb-DBS in HAB Mice
-------------------------------------------------------

### Alteration of challenge-induced neuronal activation patterns

The NAcb receives projections from the main monoaminergic nuclei including the raphe nuclei and the locus coeruleus and from regions associated with locomotion, emotion, and memory, including the globus pallidus, the amygdala, the cortex, and the HPC ([@bib61]. In turn, NAcb projects to pallidal and nigral complexes, to cortical areas such as the medial prefrontal cortex, and to the thalamic and hypothalamic regions. Several of these brain areas have been implicated in the pathophysiology of depression and/or in the processing of antidepressant effects ([@bib41]). Furthermore, many of these areas are positioned along the superolateral arm of the medial forebrain bundle, a structure related to the reward circuitry, likely to be stimulated by most of, if not all, the different electrode placements (eg the anterior limb of the internal capsule, the subgenual cingulate gyrus, the NAcb) used in the treatment of TRD patients ([@bib9]). Regarding potential mechanisms of action identified so far, DBS preferentially modulates network fibers passing the electrode, while local effects of DBS on somatodendritc structures are minor ([@bib55]; [@bib56]; [@bib62], [@bib63]). Specifically, direct inhibition of the electrode target area by muscimol injections or radiofrequency lesions does not seem to resemble effects of DBS on anxiety/depression networks ([@bib29]; [@bib65]). To identify distant parts of circuitries affected by NAcb-DBS at the present stimulation conditions, which may underlie the antidepressant effect observed in HAB mice, we used c-Fos mapping in specific brain areas ([@bib75]). The focus was laid upon those brain areas that have been previously shown to be associated with therapeutic modulation of enhanced depression-like behavior ([@bib59]; [@bib66]; [@bib87]).

One candidate area is the HPC, a highly stress-sensitive key brain structure dysregulated in depression ([@bib20]; [@bib38]) in terms of reduced volume and dysfunctional activation under emotional challenge ([@bib36]; [@bib45]; [@bib57]; [@bib77]; also see [@bib14]). Interestingly, HAB rats ([@bib59]; [@bib67]), and more recently HAB mice ([@bib60]; [@bib66]), display hypoactivation of the dentate gyrus (DG) by stress challenge. Here, we observed that NAcb-DBS enhanced the c-Fos induction in response to FST stress, suggesting that (i) neuronal DG activity is restored in HAB mice, and (ii) DG activity is strongly correlated with depression-like behavior. To our knowledge, so far changes in DG/HPC activity have not been reported in TRD patients undergoing DBS, while activity of the HPC is enhanced in addicted patients undergoing NAcb-DBS ([@bib31]).

In addition, the c-Fos response was enhanced in the OFC and the lateral habenula, but attenuated in the prelimbic cortex following FST. In line with our results, pERK expression is enhanced in prefrontal regions, including the OFC, following ventral striatum/NAcb-DBS, suggesting functional connectivity between these spatially distinct structures ([@bib65]). In further support of our findings, [@bib53], [@bib54]) propose an antidromic activation of NAcb-input fibers descending from the OFC by NAcb-DBS, resulting in the modulation of activity within the OFC and, thus, potentially affecting disturbed communication between prefrontal areas, limbic areas, and the OFC in an ultimately beneficial way.

### NAcb-DBS enhanced the number of immature neurons in the DG of the HPC

Whereas stress as a triggering factor for depression attenuates adult neurogenesis in the HPC, antidepressant treatment enhances proliferation and survival in the hippocampal neurogenic niche and has been proposed to be at least partially required for antidepressant efficacy (for a review see [@bib68]). Given that HAB mice display reduced adult hippocampal neurogenesis in comparison with NABs ([@bib66]), we also investigated whether the blunted neurogenesis of HABs would be affected by NAcb-DBS. Indeed, the number of DCX-positive cells was enhanced in the DG in NAcb-DBS-treated HAB mice in comparison with NAcb-sham controls. This finding points towards enhanced adult hippocampal neurogenesis, as DCX is exclusively expressed in neuronal precursors and not fully differentiated neurons reflecting the developmental stages of neuroblast 1 and 2 cells as well as immature neurons (for a review see [@bib17]). Similarly, DBS of the anterior thalamic nucleus slightly increases the number of neuroblast 1 cells in the HPC, while the symmetric division of amplifying neuronal progenitors is its main effect ([@bib17], [@bib16]; [@bib78]). To gain insight into the effect of NAcb-DBS on different developmental stages of newly born cells, BrdU staining was used. Interestingly, only when BrdU was injected before, but not during NAcb-DBS, an enhanced number of BrdU-positive cells was found. These results suggest that the higher number of DCX-positive neurons reflects a cell cohort, which was actually born before the NAcb-DBS intervention and whose survival was then increased by NAcb-DBS. This is supported by a recent study showing that a single DBS session of the entorhinal cortex increases the survival rate of cells born up to 10 days before DBS in the DG ([@bib76]). In this context, it is speculated that 1- to 3-week-old progenitors are especially sensitive to life events that promote survival (eg environmental enrichment) or deteriorate it (eg through stressful condition; [@bib91]). However, future work will need to verify whether these cells contribute to the reduction of depressive symptoms.

In summary, the data presented here demonstrate that NAcb-DBS selectively rescued the enhanced depression- and anxiety-related behaviors in an SSRI-resistant psychopathological mouse model of high trait depression/anxiety without affecting these behaviors in normal depression/anxiety NAB controls. The specific changes that occurred in challenge-induced neuronal activation suggest that the beneficial effects of NAcb-DBS are mediated via a distributed network that includes the HPC, and cortical and thalamic areas. Furthermore, enhanced adult neurogenesis following repeated NAcb-DBS indicates that long-term alterations may also be an important part of the mechanism(s) of NAcb-DBS, leading to a rescue of exaggerated anxiety- and depression-like symptoms.
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![Sensitivity of high anxiety-related behavior (HAB) mice to chronic treatment with selective-serotonin reuptake inhibitors. Relative to their normal depression/anxiety (NAB) counterparts, untreated HAB mice displayed enhanced depression-like behavior, as indicated by an increased period of immobility in the forced swim test. Chronic treatment with citalopram (CIT) (10 mg/kg, *per os*), paroxetine (PAR) (10 mg/kg, *per os*), or fluoxetine (FLX) (18 mg/kg, *per os*) was not able to rescue the depressive phenotype of HABs. Data represent means±SEM. *N*=8--10 animals per group. ^*\#\#\#*^*P*\<0.001 for untreated control (CTL) HAB *vs* untreated CTL NAB mice.](npp201321f1){#fig1}

![Experimental details of deep brain stimulation of the nucleus accumbens (NAcb-DBS) studies performed in high anxiety-related behavior (HAB) mice. (a) Timeline of NAcb-DBS experiments. Following surgery and recovery, NAcb-DBS was performed for 1 h per day for 7 consecutive days, whereas 5-bromo-2′-deoxyuridine (BrdU) was injected for 4 days. Effects of single and repeated (7 × ) NAcb-DBS on depression- and anxiety-like behavior was assessed by forced-swim test (FST), tail suspension test (TST), and novelty suppressed feeding test (NSF). Locomotor activity was measured in the open field (OF). (b) Schematic figure (retrieved from [@bib22]) showing the localization of the electrode tips of all animals that participated in this study. Closed circles represent NAcb-DBS; open circles represent NAcb-sham animals.](npp201321f2){#fig2}

![Effect of single and repeated deep brain stimulation of the nucleus accumbens (NAcb-DBS) on depression- and anxiety-related behaviors in high anxiety-related behavior (HAB) mice. Repeated (7 × ), but not single, NAcb-DBS robustly decreased the period of immobility during the forced swim test (a) and the tail suspension test (b), demonstrating antidepressant effects. Four repetitions of NAcb-DBS reduced the latency to eat the preferred food offered in the center of the testing area during the novelty suppressed feeding paradigm (c), indicating an anxiolytic effect. Data represent means±SEM. *N*=7--11 animals per group; *\*\*P*\<0.01, for NAcb-DBS *vs* NAcb-sham HAB mice.](npp201321f3){#fig3}

![Effect of repeated deep brain stimulation of the nucleus accumbens (NAcb-DBS) on adult hippocampal neurogenesis in high anxiety-related behavior (HAB) mice. 7 days of NAcb-DBS enhanced the number of doublecortin-positive (DCX+) cells in the dentate gyrus of the entire hippocampus (a, c and e, g). 5-Bromo-2\'-deoxyuridine (BrdU) injection before NAcb-DBS resulted in an enhanced number of BrdU-labeled cells in the dentate gyrus of the hippocampus (b, d), whereas the number of BrdU-positive cells born during NAcb-DBS did not differ between treatment groups (f, h). Representative photographs (scale bar=100 *μ*m) showing DCX- and BrdU-positive cells in the dentate gyrus of the hippocampus of NAcb-DBS and NAcb-sham HAB mice when BrdU was injected either before NAcb-DBS (c, d) or during NAcb-DBS (g, h). Data represent means±SEM. *N*=9-10 animals per group; *\*P*\<0.05 for NAcb-DBS *vs* NAcb-sham HAB mice.](npp201321f4){#fig4}

![Effect of repeated deep brain stimulation of the nucleus accumbens (NAcb-DBS) on c-Fos induction in high anxiety-related behavior (HAB) mice following swim stress. With the help of a mouse brain atlas ([@bib22]), those selected brain regions in which c-Fos expression was quantified were delineated in representative photographs comparing NAcb-DBS and NAcb-sham HAB mice. High magnification photographs of c-Fos expression are inserted for selected brain regions (scale bars as indicated). LHb, lateral habenula; MHb, medial habenula; DG, dentate gyrus; HPC, hippocampus; lOFC, lateral orbitofrontal cortex; fmi, forceps minor of the corpus callosum; PrL, prelimbic cortex; IL, infralimbic cortex.](npp201321f5){#fig5}

###### Effects of NAcb-DBS in HAB Mice on Locomotor Activity Displayed in the Open Field Test

  **Time frame (min)**   **NAcb-Sham (cm)**   **NAcb-DBS (cm)**
  ---------------------- -------------------- -------------------
  0--5                   1101±123             1200±151
  6--10                  1268±59              1047±115
  0--10                  2368±148             2248±242

Data represent the distance traveled (in cm) in the open field and are given as means±SEM. *N*=8--10 animals per group.

###### Modulation of Swim Stress-Induced c-Fos Expression by NAcb-DBS in HAB mice

  **Brain regions (brain level)**                    **HAB-Sham**   **HAB-DBS**    ***P*-value**
  -------------------------------------------------- -------------- ------------- ---------------
  *Cortical areas*                                                                
   Prelimbic cortex (+1.94 mm and +1.70 mm)          15.8±0.5       13.3±0.5        ***0.008***
   Infralimbic cortex (+1.94 mm and +1.70 mm)        11.7±0.4       13.0±0.6           0.163
   Cingulate cortex 1 (+1.94 mm and +1.70 mm)        31.6±2.4       34.2±2.7           0.706
   Orbitofrontal cortex, lateral (+1.94 mm)          33.4±3.7       43.3±2.0        ***0.027***
                                                                                          
  *Thalamus*                                                                      
   Lateral habenular nucleus (−1.06 mm)              50.9±1.8       57.8±0.9        ***0.003***
   Medial habenular nucleus (−1.06 mm)               28.9±1.1       28.0±2.6           0.770
                                                                                          
  *Hippocampus*                                                                   
   Dentate gyrus (−0.94 to −3.80 mm)                 3040±137.2     3664±234.7      ***0.040***
   Dentate gyrus, superior arm (−0.94 to −3.80 mm)   2356±98.6      2924.3±94.0    ***\<0.001***
   Dentate gyrus, inferior arm (−0.94 to −3.80 mm)   738.7±57.7     911.0±66.4         0.068

Data represent means±SEM numbers of c-Fos-positive cells per 0.01 mm^2^ (except dentate gyrus of the hippocampus where total c-Fos expression was quantified). *N*=9--11 animals per group.Bold and italic numerals indicate significant differences in the number of c-Fos-positive cells between Nacb-DBS and NAcb-sham HAB mice. *P*\<0.05.

[^1]: The first two authors contributed equally to this work
